Simon J. Hall

Source: Wikipedia, the free encyclopedia.
Simon J. Hall
Nationality
minimally invasive surgery
Scientific career
Fieldsurology

Simon J. Hall is an American researcher who is the Associate Professor and Kyung Hyun Kim, M.D. Chair of Urology and Assistant Professor, Department of Gene and Cell Medicine at The

Mount Sinai Medical Center, both in New York City.[1][2]

Hall is the author of four book chapters and more than 30 peer-reviewed articles. He has received fourteen grants and was listed among New York Magazine’s Best Doctors in 2007, 2008 and 2009.[3][4]

Biography

Hall received his B.A. in biology in 1983 from Columbia College, Columbia University and his M.D. in 1988 from the Columbia University College of Physicians and Surgeons. His postdoctoral training included an internship and a junior residency in the department of surgery at The Mount Sinai School of Medicine. He was Chief Resident in the Department of Urology at Boston Medical Center and completed a fellowship in uro-oncology at Baylor College of Medicine.[1]

From 1997 until 2001 Hall was the director of the Department of Urology at Elmhurst Hospital in Queens. In 2001, he was named director of the Barbara and Maurice Deane Prostate Health and Research Center at The Mount Sinai Medical Center, and in 2003 he was named Chair of Mount Sinai's Department of Urology. In 2009, he was named the Kyung Hyun Kim, M.D. Chair in Urology.

Hall's area of research is primarily

minimally invasive treatment options.[2]

Awards

Clinical trials

  • Autologous PAP-loaded dendritic cell vaccine (APC8015, Provenge) in patients with non-metastatic prostate cancer who experience PSA failure after radical prostatectomy. Sponsor: Denedron Corp, GCO#01-0592.[5]
  • Autologous PAP-loaded dendritic cell vaccine (APC8015, Provenge) in patients with hormone refractory disease. Sponsor: Dendreon Corp.[6]
  • A Randomized, Multicenter, Single Blind Study in Men with Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen (P07-2) Sponsor: Dendreon Corp, GCO #08-0813.[7]

Book chapters

Partial list:

  • Thompson, TC, Timme, TL, Hall, SJ, and Stapleton, AMF. Perspectives on the Molecular Biology of Prostate Cancer, In Vogelzang, NJ, Scardino, PT, Shipley, WU, and Coffey, DS. (Eds.) Comprehensive Textbook of Genitourinary Oncology, Williams & Wilkins, Baltimore, MD, 1996.
  • Hall SJ, Kresina TF, Trauger R, and. Conley BA. Gene Therapy for the Treatment of Cancer, In Kresina TF (Ed.), An Introduction to Molecular Medicine and Gene Therapy, John Wiley & Sons, New York, NY. 2001.
  • Millikan RE and Hall SJ. New Possibilities in Systemic Treatment for Metastatic Bladder Cancer, In Droller MJ (Ed.), Bladder Cancer: Current Diagnosis and Treatment, Humana Press, Totowa, NJ. p. 393-422, 2001.

Publications

Partial list:

References

  1. ^ a b "Mount Sinai Hospital - Doctor profile". Archived from the original on 2008-08-31. Retrieved 2010-02-07.
  2. ^ a b "Mount Sinai Medical Group Surgeons Perform Robotic Cystoprostatectomy For Bladder Cancer". Medical News Today. Retrieved 2010-02-07.
  3. ^ "Castle Connolly Medical Ltd". Retrieved 2010-02-07.
  4. ^ Columbia University "Alumni News Online". Alumni News. Archived from the original on 2008-10-11. Retrieved 2010-02-07.
  5. ^ National Institutes of Health "Gene Therapy for Prostate Cancer That Returns After Radiation Therapy". ClinicalTrials.gov. May 10, 2005. Retrieved 2010-02-07.
  6. ^ National Institutes of Health "Provenge for the Treatment of Hormone Sensitive Prostate Cancer (PROTECT)". ClinicalTrials.gov. October 22, 2008. Retrieved 2010-02-07.
  7. ^ National Institutes of Health "To Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen (ProACT)". ClinicalTrials.gov. July 11, 2008. Retrieved 2010-02-07.
  8. S2CID 1912375
    .
  9. .
  10. ^ "Bladder Cancer: Current Diagnosis and Treatment". Archived from the original on 2005-06-19. Retrieved 2010-02-07.

External links